|
Anavex Life Sciences Corp. (AVXL) Valation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Anavex Life Sciences Corp. (AVXL) Bundle
Simplifier la valorisation Anavex Life Sciences Corp. (AVXL) avec cette calculatrice DCF personnalisable! Doté de Real Anavex Life Sciences Corp. (AVXL) Financials and Rajustement des entrées de prévision, vous pouvez tester les scénarios et découvrir la juste valeur d'Anavex Life Sciences Corp. (AVXL) en minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -50.9 | -55.8 | .0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 26.7 | 37.5 | -3.3 | -2.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -26.7 | -37.5 | -47.6 | -53.0 | .0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 29.2 | 152.1 | 149.2 | 151.0 | 132.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.8 | 9.1 | 3.2 | 2.7 | 2.4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 4.0 | 4.7 | 3.8 | 4.3 | 9.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -26.7 | -37.7 | -48.0 | -53.0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -.9 | -3.8 | -46.3 | -54.8 | 5.6 | -7.2 | .0 | .0 | .0 | .0 |
| WACC, % | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -7 | |||||||||
| Net Debt | -132 | |||||||||
| Equity Value | 125 | |||||||||
| Diluted Shares Outstanding, MM | 83 | |||||||||
| Equity Value Per Share | 1.50 |
What You Will Get
- Real AVXL Financial Data: Pre-filled with Anavex Life Sciences Corp.’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Anavex Life Sciences Corp.’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Anavex Financials: Gain access to precise historical data and future forecasts tailored for Anavex Life Sciences Corp. (AVXL).
- Tailorable Projection Assumptions: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic adjustments to DCF, Net Present Value (NPV), and cash flow metrics.
- User-Friendly Dashboard: Clear and concise charts and summaries for effective visualization of your valuation outcomes.
- Designed for All Experience Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-configured Excel file containing Anavex Life Sciences Corp.'s (AVXL) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make adjustments.
- Test Scenarios: Generate various projections and evaluate outcomes without delay.
- Make Decisions: Leverage the valuation results to inform your investment choices.
Why Choose This Calculator for Anavex Life Sciences Corp. (AVXL)?
- Accurate Data: Real Anavex financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your projections.
- Time-Saving: Pre-built calculations save you from starting from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing portfolios involving Anavex Life Sciences Corp. (AVXL).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Anavex Life Sciences Corp. (AVXL).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to biotech companies.
- Biotech Enthusiasts: Gain insights into how biotech firms like Anavex Life Sciences Corp. (AVXL) are assessed in the market.
What the Template Contains
- Pre-Filled DCF Model: Anavex Life Sciences Corp.'s (AVXL) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Anavex Life Sciences Corp.'s (AVXL) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.